<DOC>
	<DOCNO>NCT01522040</DOCNO>
	<brief_summary>This prospective randomized pilot study seek address research question : In child moderate-to-severe asthma , intravenous magnesium infusion add standard Pediatric intensive care unit ( PICU ) -level asthma care significantly decrease time patient presentation PICU discharge ?</brief_summary>
	<brief_title>Pilot Study Magnesium Infusions Pediatric Asthma</brief_title>
	<detailed_description>This study double-blind , prospective randomize pilot study . Subjects randomize 1:1 basis receive routine asthma care without magnesium drip .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>Age 2 year 0 day 20 year 364 day Clinical diagnosis asthma include follow : Attending physician 's primary work diagnosis status asthmaticus Results modify International Study Asthma Allergies Children ( ISAAC ) diagnostic questionnaire consistent asthma diagnosis Planned PICU admission moderatetosevere asthma exacerbation persist despite standard firsttier therapy ( systemic corticosteroid least onehour treatment nebulized albuterol/ipratroprium equivalent ) evidence asthma score 7 great IV access equivalent Ability understand give inform consent/assent English Prior enrollment study Prior adverse reaction magnesium Use systemic corticosteroid magnesium precede 2 week , administer transfer facility 3 hour prior enrollment Admission inpatient asthma care precede 2 week Hemodynamic instability , impend respiratory failure intubation Inability child age 7 year older give assent due developmental delay alter mental status Significant renal cardiac disease Sickle cell anemia Significant , active nonasthma pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Magnesium</keyword>
	<keyword>Adrenergic Receptor</keyword>
</DOC>